These are peer-reviewed supplementary tables for the article ' Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain ' published in the Jo
Background Expanding the indication of already approved immuno-oncology drugs presents treatment opportunities for patients but also strains healthcare systems. Cost-based pricing models are discussed
Present cost-effectiveness analysis of nivolumab monotherapy vs commonly prescribed third-line (3L+) treatment in small cell lung cancer (SCLC). A three health states partitioned survival model (prog
Objectives: Perennial allergic rhinitis (PAR) is common in Japan. Second-generation antihistamines (SGAs) are commonly used for its treatment; however, it remains unclear which SGA is the most cost
Amid increasing awareness regarding opioid addiction, medical marijuana has emerged as a substitute to opioids for pain management. Concurrently, opioid manufacturers are putting significant research
